Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 101 results found. Search for [ studies on vaccine efficacy ]

Results 1 to 21 of 101
PTI
June 19, 2021
The New York City Health Department said in its recent update that out of the 105 NYC COVID-19 cases tested for variant viruses for the week ending June 5, the Delta variant constituted 6.7%


BusinessToday.In
May 23, 2021
Efficacy against COVID-19-linked disease averaged around 85% after a full course, increasing to almost 100% protection against severe disease, hospitalisation or death, say University of Florida researchers


BusinessToday.In
April 28, 2021
\"Initial positive neutralisation studies of B.1.617, with both post-Covaxin or Covishield sera, are correlatable with milder disease during post-vaccination breakthrough infections,\" says Anurag Agrawal, Director, Institute of Genomics and Integrative Biology


Reuters
April 19, 2021
The South African variant, B.1.351, was found to make up about 1% of all the COVID-19 cases across all the people studied, according to the study by Tel Aviv University and Israel's largest healthcare provider, Clalit


Reuters
April 19, 2021
Sarah Walters, AstraZeneca's Austria country manager said so far, indicating the existing AstraZeneca vaccine was less effective against the more infectious variant first documented in South Africa were \"too small to draw final conclusions\"


Reuters
April 10, 2021
A follow-up study of 33 people who received Moderna Inc's COVID-19 vaccine in early trials show the antibodies it induced are still present six months after the second dose


Associated Press
April 3, 2021
The teens will be added to an ongoing study of the vaccine in adults that began last September, the New Brunswick, New Jersey-based drugmaker said Friday


BusinessToday.In
April 1, 2021
The vaccine was also effective in South Africa, where B.1.351 lineage of the virus is prevalent. It said nine cases of COVID-19 were observed in the country, all in the placebo group.


Reuters
March 30, 2021
The risk of infection fell 90% by two weeks after the second shot, the study of nearly 4,000 US healthcare personnel and first responders found


BusinessToday.In
March 27, 2021
SII has signed an agreement with Novavax to manufacture a vaccine with the name 'Covovax' in India. Novavax has announced final efficacy of 96.4 per cent against original COVID-19 virus. Novavax with Serum will provide 1.1 billion cumulative doses for COVAX Facility


BusinessToday.In
March 22, 2021
Premas Biotech in collaboration with American firm Oramed Pharmaceuticals Inc had announced on March 19 that they are developing an oral COVID-19 vaccine candidate that has shown efficacy upon administration of a single dose


Joe C Mathew
March 22, 2021
Virchow is the fifth Indian company to have an agreement with RDIF on Sputnik V. Dr Reddy's Laboratories was the first to announce a tie-up with RDIF to conduct the bridge studies (clinical trials) of Sputnik V vaccine


BusinessToday.In
March 18, 2021
The study, posted in the preprint server medRxiv, stated that the woman was administered a single dose of the Moderna mRNA vaccine at 36 weeks and three days of her gestation period


BusinessToday.In
March 16, 2021
Although no links are found to be proven between the vaccine and the events, experts have cautioned that the suspension of the AstraZeneca-Oxford University vaccine may impair already feeble public confidence in the vaccine


BusinessToday.In
March 16, 2021
World Health Organisation's chief scientist Dr Swaminathan said that six-to-eight vaccines are likely to finish clinical studies and undergo regulatory review by the end of the year


BusinessToday.In
March 4, 2021
Bharat Biotech published the interim efficacy report of phase 3 clinical trial on its COVID-19 vaccine, officially known as Covaxin. The indigenous COVID-19 vaccine is found to be 81 per cent effective in preventing the virus


PB Jayakumar
March 3, 2021
So far, the Pfizer-BioNTtech and Moderna vaccines, made through a novel platform technology never used in humans before, are proven to have maximum efficacy


Joe C Mathew
March 3, 2021
The interim efficacy trend of 81 per cent, analysed as per the protocol approved by the Drugs Controller General of India, puts it at par with other global front-runner vaccines, stated ICMR


Reuters
March 1, 2021
Providing a final clearance for the vaccine a day after it was authorized by U.S. regulators, the Advisory Committee on Immunization Practices (ACIP) voted 12-0 to recommend the vaccine from J&J as appropriate for Americans 18 and older


Associated Press
February 27, 2021
The Food and Drug Administration is expected to quickly follow the recommendation and make J&J's shot the third vaccine authorised for emergency use in the US


PAGES 1 OF 6  12345